University of the Pacific

Scholarly Commons
School of Pharmacy Faculty Articles

Thomas J. Long School of Pharmacy

6-30-2021

Does Covera-19 know ‘when to hold ‘em or ‘when to fold ‘em? A
translational thought experiment
Gerald Dieter Griffin
University of the Pacific, K6nd@aol.com

Follow this and additional works at: https://scholarlycommons.pacific.edu/phs-facarticles

Recommended Citation
Griffin, G. D. (2021). Does Covera-19 know ‘when to hold ‘em or ‘when to fold ‘em? A translational thought
experiment. Translational Medicine Communications, 6(1), 1–17. DOI: 10.1186/s41231-021-00090-5
https://scholarlycommons.pacific.edu/phs-facarticles/645

This Article is brought to you for free and open access by the Thomas J. Long School of Pharmacy at Scholarly
Commons. It has been accepted for inclusion in School of Pharmacy Faculty Articles by an authorized
administrator of Scholarly Commons. For more information, please contact mgibney@pacific.edu.

Griffin Translational Medicine Communications
https://doi.org/10.1186/s41231-021-00090-5

(2021) 6:12

REVIEW

Translational Medicine
Communications

Open Access

Does Covera-19 know ‘when to hold ‘em or
‘when to fold ‘em? A translational thought
experiment
Gerald Dieter Griffin1,2

Abstract
The function of proteins depends on their structure. The structural integrity of proteins is dynamic and depends on
interacting nearby neighboring moieties that influence their properties and induce folding and structural changes.
The conformational changes induced by these nearby neighbors in the micro-environmental milieu at that
moment are guided by chemical or electrical bonding attractions.
There are few literature references that describe the potential for environmental milieu changes to disfavor SARSCoV-2 attachment to a receptor for survival outside of a host. There are many studies on the effects of pH (acid and
base balance) supporting its importance for protein structure and function, but few focus on pH role in extracellular
or intracellular protein or actionable requirements of Covera-19.
‘Fold ‘em or Hold ‘em’ is seen by the various functions and effects of furin as it seeks an acidic milieu for action or
compatible amino acid sequences which is currently aided by its histidine component and the structural changes
of proteins as they enter or exit the host. Questions throughout the text are posed to focus on current thoughts as
reviewing applicable COVID-19 translational research science in order to understand the complexities of Covid-19.
The pH needs of COVID-19 players and its journey through the human host and environment as well as some
efficacious readily available repurposed drugs and out-of-the box and easily available treatments are reviewed.

Introduction
Interest is redirected to the receptor surroundings and
intracellular organelle environment by focus on furin
and pH as two basic pillars of this translational thought
experiment to demonstrate the importance for understanding some of the important science underlying
COVID-19’s journey in humans. Using the current viral
pandemic as a life saving model for therapeutic intervention by vaccines only and not other than ‘vaccine’
methods places ideational restrictions and impedes new
treatment potentials. Several other treatment modalities
for COVID-19 are introduced and supported by elegant
studies and proven science. Viral activity, surface
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glycoproteins and interacting partners are affected by
pH changes. Heat of ~104F [1] and washing/wiping surfaces with liquids/water and at a basic [alkaline] pH are
important as are removable and replaceable paper or
plastic covers on surfaces changed after every use.
The literature has exploded with hundreds of studies
and reports on the various symptoms, demographics,
outcomes and massive numbers of new facts regarding
the current novel human pathologic agent SARS-CoV-2.
The names 2019-nCoV or SARS-CoV-2 (the virus) and
COVID-19, Covera-19 or Covera (the illness) are simplified herein to “CV19”.
The current appropriate priorities (washing, masking,
social distancing, testing, tracking and isolation) will reduce new infections, if strictly enforced, available or doable. The psychological societ al costs and results of
population-wide fears and anxieties induced by unscientific actions at all levels are not addressed in this paper.
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The complexities of CV19 illness in the context of
prior comorbid conditions, the many locations of receptor sites and mutations, based on the early New York
hospitalization experience [2], are demonstrated and discussed using the early New York City model described
below.
A study of the presenting symptoms of CV19 from
5700 hospitalized patients in the New York City area
from March 1, 2020 to April 1, 2020 revealed ~ 60%
males and ~ 40% females. The most common comorbidities were hypertension [~ 57%], obesity [~ 42%], and diabetes [~ 34%]. The presenting symptoms were fever [~
31%] and a respiratory rate greater than 24 breaths per
minute in ~ 17%, with ~ 28% of those receiving supplemental oxygen. Co-morbidities include cancer, cardiovascular disease [arrhythmias, ischemia, coronary artery
disease (CAD), and congestive heart failure (CHF)],
hypertension, asthma, COPD/emphysema, obstructive
sleep apnea, obesity and older age. Few patients [6.1%]
had no comorbidities immune suppression, aids/HIV,
history of organ transplant, renal disease, liver disease,
smoking (~ 16%). All patients tested positive by the second test for CV19. Of the patients admitted to the intensive care unit (ICU) for intensive care and ventilation
support [~ 20% of 5700, or 1151 ICU admissions], ~ 25%
or 282 ventilated patients died [2]. The requirement for
ventilation represents ~ 2.28% of the total studied patient population. The mortality rate may continue to
decrease as treatment improves and the number of
tested asymptomatic CV19-negative or asymptomatic
CV19-positive patients increases, assuming that the
whole population is tested. Testing and measuring
‘hotspots’ measures ‘hotspots’ only and not whole
population numbers may not be statistically valid, and
are easily manipulated. The CV19 morbidity and mortality numbers cannot be accurate until the whole
population is tested regardless of symptoms so a true
population basis can be established for true statistical
population comparison.
CV19 continues to prove that it is a potential serious
threat to many populations, with some requiring rapid
intervention and comprehensive care. Children are not
as ‘immune’ to CV19 infection as initially thought. A recent JAMA article reported the clinical characteristics of
many children with a pediatric inflammatory syndrome
temporarily associated with CV19 [3], now called multisystem inflammatory syndrome in children (MIS-C),
which can affect the heart, lungs, kidneys, brain, skin
and eyes [4]. Is there a prolonged post-infection survivor
syndrome in some patients? The T-lymphocytes are active but may potentially not be as effective as needed? A
pandemic phylogenetic analysis of 84 distinct CV19 genomes in New York revealed entry paths from the US,
Europe and the New York area [5].
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The mortality statistics exhibit an elevated rate since
many deaths are counted as due to CV19 if they are connected in any way. Deaths counted as ‘due to CV19’ actually may occur due to overwhelming sepsis and/or
pneumonia. In reality, ‘due to CV19’ is a contributing
factor that can be listed on its own line on the death certificate beneath the potential actual cause of death.
Ventilator-treated CV19 patients who die have profound
hypoxemia and may die of a myocardial infarction from
insufficient oxygen or perhaps an arrhythmia. The immediate cause of death is myocardial infarction due to
hypoxemia due to CV19 contributory effects (pneumonia or inflammation etc). Other practices are built into
various semantics, as death certificate signers decide on
death data certification. This is also found in other infectious diseases, such as influenza or HIV for example,
which also have pneumonia and inflammation as comorbidities, but the cause of death is listed commonly as
Influenza and HIV/AIDS. Obviously this common practice is not strictly accurate, but is the current practice.
Support for this reality has finally arrived from the National Center for Health Statistics, which states that only
6% of CV19-specific deaths are truthfully countable [6,
7]. Death ‘from’ CV19 is different from death ‘with’ or
‘due to (addition of)’ CV19. These separate lines are selfexplanatory on the death certificate.
CV19 must accomplish the following in order to sustain itself and to multiply: Find a host > attach to and
bind its receptor with the S1 spike protein > enter and
travel through the receptor > initiate cell membrane fusion > create a pore and pass through to inside the host
cell > enter an endosome > shed and leave the endosome to find the Host DNA and begin and finish the
replication cycle > re-enter an exosome and travel to the
host membranes > and ‘exit’ the host cell. The exit and
leaving the exosome to ‘exit’ are not well established.
Each of these steps has its own requirements and complexities including energy sources.
The mouth/oropharynx and nose as entrances for
CV19-laden air and ‘droplets’ provide a direct path to
the oropharynx, trachea, and lungs but also provide
receptor sites along the way [8–10]. Two important
angiotensin receptor blocker (ARB) proteins (ACE2[angiotensin converting enzyme 2] and TMPRSS2 [transmembrane protease serine 2]) are strongly expressed in
nasal passage goblet secretory cells, type II pneumocytes
of the alveoli in the lungs, and absorptive enterocytes of
the intestine-ileum and lower bowel [9, 10].
Masking and distancing are important in personal prevention of both oral and nasal CV19 entry by potential
aerosol and ‘droplet’ contagion. Masking does double
duty—it prevents spread from infected patients with or
without symptoms via CV19 aerosols or ‘droplets’ into
the nasal passages and mouths/oropharynx of uninfected
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victims, and protects uninfected patients wearing masks.
Surface contamination sources are a separate problem.
Ziegler et al. [9] noted other entry points and receptor
site locations for CV19: the conjunctivae of the eyes, the
epidermal surfaces of blood vessels, and the tissue targets of viral spread via blood vessels to target organs. Is
an open wound or absent skin [i.e., burns] an opening
for CV19? Burns and wounds expose blood vessels with
receptor sites. The target organs include the eyes, lungs,
heart, all types of blood vessels, brain (neural cortex and
brain stem, spinal fluid), nose, liver, kidneys and intestines (ileal sites or lower bowel) [10].
The conjunctival entry point in the eyes presents special problems in covering and protection—perhaps wearing glasses may help, but that is questionable. In later
CV19 illnesses, this entry may lead to conjunctivitis and
be potentially restricted by tear production in response
to irritation from CV19 presence. The conjunctivae also
have goblet cells with a potential role in CV19 systemic
spread. What is the role of tears or ocular fluids in combatting CV19 entry? Are the epidermal surfaces of blood
vessels in the conjunctivae facilitating systemic CV19
entry? The pH of the conjunctival goblet cells and tears/
ocular fluids was measured at pH 6.3/6.5 to 7.23/7.6 [11,
12], which may be advantageous to CV19 and its preference for acidic site activity. It is reported that borate
may be a pH buffer in the conjunctivae and ocular fluids
[11]. The conjunctivae as entry sites have been overshadowed by the emphasis on oral and nasal entry portals,
hence the conjunctival CV19 entry site has received less attention and study. Loss of eyesight or ocular damage has
not been mentioned in the CV19 literature. Does the higher
pH range in the conjunctivae denature CV19 ‘S’ protein so
it cannot be cleaved by furin for spike S1 subunit-receptor
attachment? What is the furin level in the conjunctival goblet cells compared to oral and nasal passage sites? The answer may lie in the environmental milieu of the
conjunctivae, which is bathed by tears and other ocular
fluids. The conjunctival CV19 entry portal may support
using a plastic facial mask that also covers the eyes as a superior infection barrier. The facial plastic mask may also
limit PPE exposure from CV19 positive patients.
The gastrointestinal tract may be a ‘pass-through’ site
for shed viral shells and proteins [10], but can also be an
entry site from any source or from self-infection by
asymptomatic positive individuals. The widespread systemic ACE2 and ARB (angiotensin converting enzyme 2
and angiotensin 2 receptor blocker sites) receptor distribution and viral entry may lead to multi-organ illness or
potential multi-organ collapse and death.

CV19’s intracellular journey and actions
Protein structure dictates function. Local environmental
chemically or electrically induced conformational and
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structural changes [denaturation] may enhance or prevent agonist and host receptor proteins from interacting.
Does ARB/ACE2 display a feedback loop in the CV19
entry process? After CV19 enters the cell via the ACE2/
ARB receptor, uncoating of both CV19 and host membranes during the fusion process occurs, and the singlestranded RNA genome enters into the host cell cytoplasm via endosomal transport.
CV19 then initiates its reverse RNA reproduction cycle
leading to eventual ‘exocytosis’, as its newly formed virions exit from inside newly formed exosomes to seek a
new host cell’s ACE2/ARB receptors and repeat the
process. The host is re-infected in a continuously
expanding infection, both intracellularly and systemically. Are RNAs are made early from the first genes of
the host DNA genome, and are multiple copies made?
What is the fidelity of the subsequent mRNAs templated
from the host DNA? Could these multiple copies be
other sources of mutations if strict copying fidelity is not
observed [13]? Where on the CV19 RNA and in what
time-frame are the promoter and terminator genes active, if present at all? Where and when, early or late, on
the CV19 RNA is this specific reverse transcriptase gene
found? Is an enzyme involved in the production and initiation of this particular RNA reverse transcriptase?
What will comparison with HIV reverse transcriptase
models show? Could the built-in ‘degeneracy’ in the triplet genetic code (a different triplet code for the same
amino acid in the mammalian genome) also be a potential adaptive evolutionary mechanism in CV19, as it uses
only its RNA? It is generally accepted that, like poliovirus, when CV19 uses its reverse transcriptase to make
its own RNA, protein synthesis ceases in the host. In
support of this, Thoms et al. recently showed that “Nsp1
(nonstructural protein 1) from SARS-CoV-2 binds to the
40S ribosomal subunit, resulting in shutdown of host
messenger RNA (mRNA) translation both in vitro and
in cells.” [14]. Ban supports this by suggesting that Nsp1
suppresses host innate immune functions and interferes
with mRNA binding, as the C-terminal domain of
SARS-CoV-2 Nsp1 binds to the mRNA entry channel
[15]. The high infection and transmissibility rate of
CV19 was found to be due to another host protein called
‘neuropilin-1’, “which is recognized and bound by
CV19’s spike protein and also facilitates CV19 cell entry
and infectivity [16].” This finding seeks urgent study and
comparison with newer emerging variants or other mutant entry proteins.
Additional intermediate conformational structures of
proteins were addressed earlier by Bai and Englander
[17], who stated that “All possible protein folding intermediates exist in equilibrium with the native protein at
naïve as well as non-naïve conditions, with occupation
determined by their free energy level.” Principles of

Griffin Translational Medicine Communications

(2021) 6:12

protein structure and folding are illustrated by Walls
[18], Wrobel [19], and Wrapp [20].
PROTEIN GAME PLAYERS: ‘Hold ‘em or fold ‘em
or fold ‘em and hold ‘em?’
Wrapp et al. [20], Watanabe et al. [21] and Cai et al.
[22] report that the ‘Spike (‘S’)’ glycoprotein mediates
cell entry and cell fusion. The ‘S’ protein is described as
a “trimeric class 1 fusion protein composed of two subunits: one responsible for receptor binding (S1 subunit)
and a membrane fusion subunit on the S2 subunit. The
‘S’ protein undergoes a ‘hinge-like’ conformational
change to expose the receptor-binding domain. The
spike surface is dominated by host-derived glycans, with
each trimer displaying 66 N-linked glycosylation sites”
[21]. The ‘S1’ spike subunit binds to an amino terminal,
and the ‘S2’ spike subunit binds to a carboxyl site after
cleavage by furin [23]. Importantly, furin cleaves the ‘S’
protein of CV19 into two proteins: S1 and S2. As above,
S1 is responsible for receptor site attachment, and S2,
with its fusion peptide site, is responsible for fusion of
the CV19 and host cell membranes to allow the CV19
genome to enter the host cell [22]. These actions may
also indicate potential intrareceptor site mechanisms as
CV19 transits through the receptor site. All of the receptor interactions and intracellular activities require an energy source. Once the membranes of both the host and
CV19 are fused, the S2 fusion peptide forms a ‘fusion
pore’ allowing the CV19 genome to enter the host cell
for endosomal ‘entry’ and transportation [24].
Another potential CV19 entry-enabling protein was recently identified by Liu et al. [25]: heparan sulfate (SO4),
which is closely related to heparin. Liu et al. also demonstrated that heparan SO4 removal inhibits CV19 attachment to the ACE2/ARB receptor site. Heparan SO4 is
also known to be and described as an ‘adhesin’. Heparan
SO4 provides an attachment site for CV19, plausibly
holding it in the host receptor site area, and CV19 may
not attach to the ACE2/ARB receptor site until it has
adhered to the heparan SO4. Heparan SO4 attachment
may be an early time-dependent or controlled event, and
in this role it may enhance ‘adhesion’ of CV19 to the
ARB/ACE2 receptor for subsequent actions to proceed.
This ‘adherence and delivery’ action by heparan SO4
could be a critical early step in CV19 attachment to host
cells because it ‘guarantees’ delivery of CV19 to the host
cell receptor. Could heparan SO4 be blocked as a treatment, and the process halted at this early stage as well
with prolonging time adherent dependency? Does heparanSO4 participate in a sequential process with other
components? Heparan SO4 is a negatively charged polysaccharide that resided on the cell membrane. In the
CV19 events sequence, it is derived from the host and
onto the CV19 exterior and is ‘held’ in the host receptor
site region. As Liu described removal or inactivation of
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heparan SO4 inhibits CV19 attachment to the ACE2/
ARB receptor site [25]. Since heparan SO4 is a very
acidic moiety, could it be inactivated by creating a basic
environment and receptor site environment by pH adjustment? This may disallow an early receptor site CV19
attachment and CV19 cell entry? Hence creating an external basic environment may be an early potential
CV19 entry denial into the host cell. This proposed
model requires study and confirmation. CV19 is also
bound by heparin, which leads to the question ‘does it
uses heparin as a transport vehicle for systemic spread
and infection, as HIV does with its platelet ‘taxi’ [26]‘?
Use of heparin as a transport medium might help to explain the common coagulation problems of patients with
CV19 infection because of heparin’s potential unavailability for normal blood anticoagulation and the widespread CV19 distribution. Yu et al. showed activation of
an alternative complement pathway that blocks CV19
spike proteins [27]. Bouhaddou et al. [28] discussed the
complicated phosphorylation processes during CV19 invasion. The increase in CV19 proteins and decrease in
host proteins during various phases of phosphorylation
in the energy production cycle showed that this decrease
in host protein caused the demise of the affected host
cell by inhibiting host mRNA translation and mitotic kinases [28].

Furin
“Furin is a pro-protein convertase that cleaves the protein and amino acid chain region called ‘RXR/K/XR’ of
precursor proteins and transforms the pro-proteins into
biologically active proteins and peptides” [29]. Furin participates in many nuclear, intracellular, membrane and
endosomal actions. Furin has important roles as a proteolytic cleaver of capsular polyprotein precursors prior
to viral RNA assembly of newly made CV19 in the acidic
environment of the trans-Golgi network.
Furin is a multi-functionally important protease that
‘senses’ its needed acidic pH environment necessary for
function. The structure of furin has both an amino
group and a carboxylic acid group but a net neutral
charge, which plausibly allows ‘zwitterionic’ or dipolarlike behavior and functions. It is known that for furin action in various organelle sites requires an acidic pH [30].
The TMPRSS2 serine host protease in the receptor site
of CV19 is acidic and hence a welcome partner for furin
action. How ‘acidic’ or how ‘weakly basic’ a furin action
site must be for function is not known. Other viral
models may also provide acidic environments for furin
activity and may be models for study and potential understanding of CV19. Furin is a common denominator
in many cellular functions and acts as a ubiquitous cellular protein ‘concertmaster’. Could furin be artificially
modified and targeted to achieve desired outcomes?
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Pelleccia’s laboratory [31] identified furin as a companion protease to TMPRSS-2 in enhancing CV19 transit to
the ACE2/ARB receptor for host cell entry. Furin affects
spike glycoprotein structure cleavage in other viral evolutionary processes [19, 32] and has a long history as a
protein ‘cleaver’. A four-amino-acid insertion between
the edges of the S1 and S2 Spike protein subunits is
‘sensed’ by furin and allows furin-mediated ‘S’ protein
cleavage [33]. Roebrook et al. found that furin requires a
negatively charged four-amino-acid motif (or low-basic
four-amino-acid sequence?) in the substrate-binding region to cleave that site [34]. This action enables the
‘open pre-attachment conformation’ necessary for the
CV19 spike ‘S1’ protein subunit to attach to the ACE2
receptor site. What gene directs insertion of these four
amino acids for recognition by furin cleavage, and can it
be modified? The ubiquitous furin is present in the
ARB/ACE2 receptor site before the ‘S’ protein arrives to
be cleaved. The furin ‘S’ protein cleavage site was also
described by Coutard et al., who noted its absence in
other SARS-like coronaviruses (CoVs) [33]. The absence
of the ‘S’ protein furin cleavage site in other SARS-like
CoV viruses is an important difference. The presence of
a four-amino-acid cleavage site attractive to furin could
indicate CV19 mutations or an unusual evolutionary
event. The S1 subunit has a basic N-terminus that binds
to ACE2/ARB, while the S2 subunit has an acidic Cterminus that interacts with TMPRSS2 and furin after
attachment for passage through the receptor site and
contains the fusion peptide. These oppositely charged
terminals may enhance furin’s ‘zwitterion’-like or ‘dipolar’ behavior and give it a greater capability to affect
other protein sites. Given that CV19 mutates frequently
for improved survival and function, any or all of the descriptions found to date and described here may change
as CV19 mutates.
Cai et al. [22] and Roebrok et al. [34] support that the
‘S’ spike protein has both a ‘prefusion’ and a ‘postfusion’
state and that it undergoes the conformational change
needed for successful host entry enabled by furin cleavage. They stated that the prefusion trimer structure has
“three receptor-binding domains adjacent to the fusion
peptide and that the postfusion structure has strategically placed N-linked glycans suggesting ‘viral protection’
against host immune responses and harsh external conditions” [22]. Wrobel et al. supported these observations
[19]: “the human CV19 pathogen presents a more stable
pre-cleavage form and an approximate 1,000-fold tighter
binding of SARS-CoV-2 to human receptor than in
bats.” They further state that “ these observations suggest that cleavage at the furin-cleavage site decreases the
overall stability of SARS-CoV-2 and [but] facilitates the
adoption of the open conformation change that is required for ‘S1’ to bind to the ACE2 receptor.”
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Furin is implicated in mutations, tumor growth, viral
and bacterial infections, protein cleavage and change
into biologically active moieties. Some approaches have
been suggested to stop furin activity. A furin inhibitor, a
2,5-dideoxystreptamine derivative, was designed to form
a complex with furin [35] but needs further evaluation.
Jean et al. [36] introduced alpha1-antitrypsin Portland as
a ‘bioengineered’ serpin molecule selective for furin inhibition. They stated that the formation of a chemical
moiety complexed with furin revealed activity inhibition
of 100% complete after 2 min of exposure and described
it as a “suicide substrate inhibitor’. Additional studies
and clinical evaluations of furin inhibitors are expeditiously needed. Cheng et al. described several other
furin inhibitors that may be useful after more supportive
studies [37]. The use of furin blockers has not received
enough attention given the critical function and presence of furin for most cell needs for protein cleavage, in
the replication process and at the cell membrane receptor site. Other entities will likely continue to be identified concerning furin function as our knowledge and
experience with CV19 or other viral agents grows [38].
Controlling and eradicating furin activity appears to be
one of the primary keys to controlling CV19 and potentially other emerging viral pathogens. This action speaks
to the fact that the singular target ‘vaccine’ focus has
sidelined this and other treatment potentials.
A requirement for furin action, as for all cellular functions, is an energy source since biosystemic function is
based on kinetic models instead of thermodynamic
models.

Mutation plays
Early in the CV19 outbreak, it became apparent that
CV19 has the capability to evolve, as initially demonstrated by its movement from animal to human hosts
[24]. This ability to mutate and adapt is still evolving.
The current intermediate protein forms of CV19 that
emerge or mutate into different structures have increased potential for infection and improved host entry
[25]. Intermediate forms may be found as new mutations
emerge and thus give rise to a dynamic structural milieu.
The ‘older’ forms will be replaced in time by the newer
mutants. The ACE2/ARB receptor accommodates the
current newly mutated form of CV19, which may signal
a small or single.
CV19 has genome mutations at position 23,403, which
are ‘adaptations’ to different geographical areas and their
populations. This phenomenon was identified again recently [39] and indicates geographical mutations and
changes toward increased infectivity. The ‘D614G’ (now
named G614) mutation changes the virus spike protein
that attaches to the CV19 receptor site. This effect partially demonstrates that an agonist can be modified for a
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better stoichiometric fit. Watanabe et al. [21] and Cai
et al. [22] showed structural CV19 spike ‘S’ protein conformational changes but no receptor site changes.
The earliest mutation version, G614, found in the
CV19 spike ‘S’ protein still ‘fits’ to the ACE2/ARB receptor protein but with stronger ability to fuse with host
membranes and an at least 3–10 times greater infection
capability, causing a mutation for improved survival but
not a large structural change while maintaining attachment ability to the ACE2/ARB receptor protein, as confirmed by Choe and Fazan [26]. As mentioned above,
G614 seeks comparison with the current ‘new’ variant to
confirm its true appearance timeline. Infectivity appears
to peak before symptom onset at ~ 4 to 7 days after exposure [23]. He et al. [40] estimated that 44% of infected
individuals were infected during the ‘pre-symptomatic’
(asymptomatic) stage within household clusters and settings. These infections are primarily from close contact,
absent masking and via aerosols, ‘droplets’ or surfaces.
The compilation of prior studies by Korber [39] also
identified the G614 mutation and supports the earlier
mutation model by Choe and Fazan [26], which shows
that the ‘G614’ mutation is almost completely dominant
in most countries and potentially now is being ‘re-discovered’. They also noted that ‘G614’ has “slightly changed the spike shape and protein structure to enhance
and ease the viral membrane and host cell membrane fusion, which also supports a potential stronger infection
rate of 3 to 10 times as before and that CV19 accumulates about two changes a month in its genome [26]“.
These data may all be or become ‘moving targets’. In a
larger sense, together with asymptomatic patients, nonmasking and non-social distancing these mutations offer
an explanation for the early and current rapid infection
wave spreading across the globe, with a stronger affinity
and infectious potential. The mutational ability of CV19
was further addressed and found to be more complex by
Berrio et al., who importantly noted genome mutations
independent of protein function impact [41].
Van Dorp et al’s report from the University College of
London characterized “patterns of diversity of the SARSCoV-2 virus genome” by identifying ~ 198 recurrent
genetic mutations [42], which may help to explain how
the virus adapts to its various environments, survival
needs and human hosts by use of this large potential
mutational repertoire. Are there epigenetic signals and
activators for the mutations that may be identified? Regarding the known potential ~ 198 recurrent mutations
[42], do they enable or guide CV19 and its ubiquitous
player furin to a specific genome domain for mutational
induction once inside the host environment in order to
be more successful? It may help to think of this mutational induction as “functional genetic flow” enabled by
‘evolutionary pressure’ which may be guided by
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epigenetic need to adapt to changing requirements? The
current mutations [or ‘variants’] may fit into the mutational potentials described above.
Baum et al. suggested developing an antibody cocktail
to prevent CV19 from developing rapid mutational escape in response to the use of individual antibodies [43].
Mutational escape may make single target neutralizing
antibody vaccines less effective. Hansen and Baum et al.
reported on potential humanized neutralizing antibody
cocktails for anti-SARS-CoV-2 use. This cocktail aims to
decrease the potential, raised by Baum et al. [43], for the
emergence of CV19 escape mutants from the use of single antibody vaccines [44]. The notion of single antibody
vaccine failure due to a more rapid mutation potential is
most concerning, and the above studies [42–44] must be
solidly confirmed expeditiously and watched for close
and appropriate response since this appears to be a
looming event. The various cocktail antibodies work
separately but synergistically. They [43, 44] also stated
that this combination cocktail of survivor antibodies
may overcome the presence of mutant forms that are
present and have escaped treatment. Duffy questions
why the CV19 mutation rates are so high [45]. The
Medical Letter lists an early summary of CV19 therapy
[46]. Konno et al. recently discovered a new interferon
(IFN) antagonist which may positively impact therapy
after confirmation and efficacy studies [47]. Impaired
IFN responses are associated with CV19 disease.
What are the furin levels at this early stage in CV19 invasion? A comparison of entry genomes of the current
mutations could indicate whether changed genomes are
found as a ‘gene in situ tweak’ mutation to enable CV19.
Could the pathologic process, once under way, induce
other and more efficient mutations? Are there are more
mutations early in the infection cycle, with fewer over
time? Perhaps the ‘zwitterionic’ furin’s ability to ‘sense’ an
acidic intracellular organelle site, adapt to its environment
and maintain activity after mutation plays a role? Current
CV19 genome testing is used as a method to determine
the geographical spread of CV19. The papers by Watanabe et al. [21], Cai et al. [22] and Wrapp et al. [20] support the question ‘hold’ em or fold’ em’ and support that
CV19 does both, depending on receptor site and intracellular actions, pH and CV19 mutational survival needs.

Repurposed therapy and modifying the agonist
and receptor
The pharmacology and biochemistry of new or repurposed drugs potentially efficacious in interfering with
extra- and intracellular CV19 actions is a broad area. It
is helpful to consider and select methods that disturb
the flow of energy in the TCA/Krebs cycle and methods
that could interfere with CV19 attempts at entry, membrane fusion for entry and exit, replication and protein
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reproduction. RNA mechanisms, furin cleavage, endoand exosome activity at entry and exit are also important
potential considerations for interfering with CV19. Every
action and function within a cell requires a source of energy, and CV19 is no different.
The Medical Letter on Drugs and Therapeutics presents a large list of potential medications for CV19.
Some potential therapeutic modalities will be discussed
here. The Medical Letter does not address mutations
and their therapy [46].
Earlier support of the protease TMPRSS-2 ‘activation’
of the CV19 Spike protein was offered by Glowacka
et al. [48], and followed by a report from Kawase et al.
[49] who used serine and cysteine protease inhibitors to
prevent SARS-CoV entry [49]. Zhou et al. also suggested
using protease inhibitors targeting CoV and select filovirus entry [50].
Hoffman et al. [51] then showed that the ‘S’ protein
action is facilitated by TMPRSS-2, which is localized to
the ACE2/ARB CV19 receptor domain. This activity also
enables CV19 attachment and entrance to the cell via
the ACE2/ARB receptor. Hoffman et al. [51] also reported that the ‘priming’ of spike agonist protein by
TMPRSS-2 was inhibited by an FDA-approved orphan
drug serine protease inhibitor, camostat mesylate, which
is currently used for pancreatitis and esophagitis in
Japan but could be available worldwide. Importantly,
Hoffman et al. found that alveolar lung cells were not invaded by CV19 if camostat mesylate was used [51]. This
is a critically important finding and therapy that has the
potential to stop CV19 in its attacks on pulmonary tissues by blocking TMPRSS-2 ‘priming’ of the CV19 ‘S’
spike protein. Note that TMPRSS-2 has a serine as a
part of its structure.
The FDA site on camostat mesylate describes its actions as follows [52]: “The mesylate salt form of camostat, an orally bioavailable, synthetic serine protease
inhibitor, with (has) anti-inflammatory, antifibrotic, and
potential antiviral activities. Upon oral administration,
camostat and its metabolite 4-(4-guanidinebenzoyloxy)
phenyl acetic acid (FOY 251) inhibit the activities of a
variety of proteases, including trypsin, kallikrein, thrombin and plasmin, and C1r- and C1 esterases. Although
the mechanism of action of camostat is not fully understood, trypsinogen activation in the pancreas is known
to be a trigger in the development of pancreatitis. Camostat blocks the activation of trypsinogen to trypsin and
the inflammatory cascade that follows. Camostat may also
suppress the expression of the cytokines interleukin-1
(IL1b), Interleukin-6 [IL6] (known to be highly present in
the lungs during CV19), tumor necrosis factor–alpha
(TNF-a), and transforming growth factor-beta (TGF-beta),
along with alpha-smooth muscle actin (alpha-SMA).
These cytokines belong to the anti-inflammatory Th2
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cellular immune response but are likely overwhelmed by
the strong inflammatory opposing response. In addition,
camostat inhibits the activity of TMPRSS2, the host cell
serine protease that mediates viral cell entry for influenza
virus and CoV, thereby inhibiting viral infection and
follow-on replication [52]. Uno described camostat mesylate and its use, dosing and efficacy [53].
A current large-scale study of camostat is ongoing by
the University of Aarhus in Denmark, with an endpoint
in March 2021 [54].
Interleukin-6 [IL-6] blockade therapy has been used to
reduce the macrophage inflammatory response, with
some success [55]. As noted above, camostat may also
block IL-6 and potentially support a stronger Th1-type
cellular immune response.
The drug remdesivir produced a statistical improvement in nonspecific clinical status compared with that
for standard care with ‘undefined clinical importance’
[56, 57] but has been approved for use. However, remdesivir may work better in combination with an IL-6
blocker or other antiviral drugs. Tortorici et al. suggested that strong human antibodies protect against
CV19 [58], while Konno et al. reported on an interferon
[IFN] antagonist [47]. Stauffer et al. mention using dexamethasone early [59].
Jurgeit et al. [60] report that the old anthelmintic drug
niclosamide inhibits adenosine triphosphate (ATP) production by uncoupling oxidative phosphorylation and
that it blocks endosomal acidification. Acidification of
endosomes and acidic environments as discussed in this
paper is a necessary environment for furin to be active
in cellular endosomes, in the ARB receptor site, the fusion process of CV19 and host membranes, as well as
Golgi body protein assembly. Niclosamide may become
very useful once tried in human clinical scenarios. Niclosamide importantly also neutralizes endosomal and
Golgi acidic environments [60]. Furin is a major actor in
the acidic environments of the ARB receptor site, Golgi
bodies and CV19 exit endosomal milieu. Further studies
are expeditiously needed on niclosamide in the context
of CV19 and other viral infections to support its potential CV19 and furin limiting actions by changing the environmental, intracellular, endosomal pH and TCA/
Krebs cycle pathways. Niclosamide is available for repurposing and has been used safely as an anthelmintic for
over 40 years in humans. Once shown to be dually useful as an oxidative phosphorylation inhibitor and organelle and endosomal pH changer in human targets or for
CV19 therapy it may become a valuable re-purposed
medication in treating CV19 or as a part of a medication
cocktail as used in other illnesses. If found to do the
same in human studies, then it can be considered safe
for use since it has been used safely for over 40 years. It
is plausibly desirable and useful for human CV19 or any
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current or potential emergent mutant or anti-viral therapy. Forty years of safe human use of niclosamide is sufficient to demonstrate recovery of its suppressive TCA/
Krebs cycle activity and follow-on continued human
health.
There are many repurposing drugs and identification
efforts described in the literature, and it is beyond the
scope of this paper cover them all. They may be useful
adjunct therapy while awaiting vaccine roll-outs as backup therapy, and efficacy expectations and results are
studied.
Each activity in the cellular milieu requires a source of
energy. This energy is derived from the ttricarboxylic
acid cycle (Krebs cycle), as it shuttles various moieties
through losses and additions of electrons and produces
adenosine tri-phosphate (ATP), which eventually becomes cyclic adenosine monophosphate (cAMP) with
serial loss of energy-laden phosphate (PO4) bonds at
various sites in the TCA/Krebs cycle. cAMP then becomes the energy source for many cellular activities, including CV19 and furin actions. The relationships
between phosphodiesterase (PDE) and cAMP are very
complex and counterintuitive but deserve much more
study for potential future understanding. If PDE is
blocked, then cAMP is able to function. An increase in
PDE could possibly prevent an energy source from enabling CV19 activity by blocking cAMP. Niclosamide [see
above] also uncouples oxidative phosphorylation, and
with its added endosomal acidic pH neutralization capability, as said, it could become a desirable drug in CV19
treatment. Aside from energy production interruption,
furin also cannot act in acidic endosomal or other action
sites without an energy source. Viral entry was also targeted as a strategy for broad-spectrum antivirals [61].
The well-described use of dexamethasone (6 mg daily)
has shown promising results in combatting the inflammatory response in the lungs as an immune suppressive
medication [59, 62]. This is a welcome short-term effect
for inflammation suppression, but long-term Decadron
or other corticosteroid use may suppress the immune
system further toward potentially undesirable consequences. The use of different corticoid steroids showed
an undefined lowering of 28-day mortality [63].

Immune plays
There are currently many ongoing studies seeking an effective vaccine in clinical trials, with some declared efficacious, safe and being administered. Many studies and
efforts have been gathered under the general term vaccine but are not a vaccine in the traditional sense. The
word vaccine brings comfort. It is concerning that every
solution to counter CV19 are single target efforts, and
that CV19 in the face of efforts to destroy or incapacitate
it may be able to change its mode of attack or molecular
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biology as it has the capability to mutate depending on
geography and adversity. Other supporting concerns are
production, distribution and cost to patients.
The effect of CV19 on the immune system appears to
be a Th1-to-Th2 cellular immunity shift that allows infections, inflammation from macrophages and other
problems to emerge. Th1 produces IFN gamma (IFN-G),
increasing inflammation early, which is desirable in
some cases of infection and illness, and Th2, whose cytokines include IL6, IL10, IP0 and macrophage inflammatory protein alpha, attract other Th2-acting
reprogrammed macrophages and increases inflammation
[64]. Via a very complicated pathway, monocyte-derived
inflammatory macrophages add to the cytokine storm
and blood coagulation pathway activation seen in late
stages of CV19.
The cytokine Interleukin-6 [IL6] is also present in
many cases, and IL6 blockade has been used with some
success in many patients with macrophage-induced inflammatory syndrome [54]. The drug tocilizumab has
been found to reduce the mortality risk of some ventilator patients by 45%, allowing them to be extubated or
out of the hospital within a month. The researchers cautioned that dexamethasone therapy is undesirable at the
same time with tocilizumab [65]. Tocilizumab is also reported to reduce cytokine release syndrome and IL6 action, reducing mortality [66, 67].
The role of monocyte-derived macrophages requires
additional evaluation, including regarding the timing of
signaling actions in order to discover their multifaceted
function. Macrophages may play different roles in different tissues and environments. An excellent description
of the complex macrophage action in the inflammatory
setting and cytokine storms is found in the papers by
Merad and Martin [64] and Schulert and Grom [55].
Macrophage-influenced ‘immune dysfunction’ or ‘overreaction’ is also commonly seen in some severe trauma
patients with total system and tissue collapse from cytokine over-reaction [68]. A pertinent and helpful discussion of macrophage activity was found in the paper by
Rydzynski-Moderbacher [69]. They pose that the macrophage response is more important than the antibody response. Macrophages derived from bone marrow
monocytes circulate until they ‘find’ an intruder to arm
themselves against and assist B cells in making antibodies and killer T cells in seeking CV19-infected cells
for elimination. Other killer T-cells may also be sourced
from survivor blood and transfused. Naïve T cells in the
bone marrow of infected patients are a reservoir of useful blood cells, including other naïve white blood cells.
The T-cells in the bone marrow could be harvested,
multiplied to billions in number and given to a patient
autologously via any available access routes. This procedure restores a ‘naïve and robust’ immune system that
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would act as a new Th1 infection-fighting immune system [70]. There are at least four ways to achieve a ‘younger and newer’ naïve immune system: by birth and
inheritance, from cord blood, by early withdrawal and
storage for need or use later [71], and by collecting a
naïve and robust immune system from the bone marrow.
If not drawn from cord blood at birth or stored later in
life when healthy [71] and no immune suppression
present, then the bone marrow site with only the white
blood cells and macrophages harvested(not the stem
cells) is always available. The white blood cells drawn
from the above sources would give one a healthier and
younger immune system to face any immunesuppressive situation or need. The bone marrow is also a
resuscitation or IV infusion site for medications. The
bone marrow reservoir of life-saving naïve white blood
cells or red blood cells is always ready and available for
extraction and use for health and/or life-saving needs.
Intraosseous access for fluid and blood products transfusions is a common standard of care if intravenous access
cannot be established. This therapeutic modality was
presented as a poster and short discussion at the 2019
American Association for Advancement of Science
(AAAS) meeting [70]. Mentioned by Charron [71] earlier
and then Griffin [70] is that each of us has a new and renewable immune system in our bone marrow. This is a
mixture with stem cells and macrophages, and the macrophages and or the stem cells may be harvested as
needed. An immune system readily available for use may
be plausibly considered as an available personal ‘vaccine’.
Absent from many reports older patients to CV19, as
a co-morbidity is the fact that the immune system is also
less functional as the patient ages. A recent timely article
poignantly suggested that an aging immune system may
allow exacerbation of CV19 illness and symptoms despite already presenting other known comorbidities [72].
Life-threatening illnesses, including pandemics, require
investigating out-of-the-box and courageous visionary
solutions based on sound science and studies.
Viral infections stimulate production of various types
of interferons [IFNs] that induce an antiviral state [73],
and some successes using IFNs to treat CV19 infections
have been reported. Ziegler et al. [9] also reported the
upregulation of ARB/ACE2 via an IFN-stimulated gene
as a host viral infection defense. IFN alpha may induce
response refractoriness, which requires close attention
and possible changing or halting of IFN therapy.
IFN alpha has been used for over 50 years for treating HIV and hepatitis B and C safely. Grajales-Reyes
and Colonna’s excellent discussion of IFN responses
offers explanation and understanding of IFN roles in
viral pneumonias [73]. The role of IFNs is complex
and may be useful for CV19 treatment once completely
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studied, including safety, IFN responses and dose timing
issues.
Studies of antibody signatures are emerging and relate
to different outcomes. In a 22-patient cohort with the
same Immunoglobin-G [IgG] levels, those who survived
had spike-specific humoral antibody responses, while
those who died had nucleocapsid-specific antibody elevations [74]. This finding was supported in an elegant
study by Peng et al. [75], who reported that CV19specific CD4+ and CD8+ T cell responses were found in
most convalescent patients, while a significantly greater
T- cell response was noted in those patients with severe
illness. They concluded that “Differential subsets of
CV19-specific T-cells can be associated with (specific)
clinical outcomes.”
Matthew et al. reported that there are three immunotype profiles in CV19 patients: 1. immunotype 1associated disease severity with a “robust activated CD4
T-cell response, a paucity of circulating follicular helper
cells (B cells? [GG]), activated CD8 T-cells, hyperactivated or exhausted CD8 cells and plasmablasts (PBs); 2.
immunotype 2 – characterized by less CD4+ cell activation, Tbet effector CD4 and CD8 T-cells, and proliferating memory B cells and not associated with disease
severity; and 3. immunotype 3-correlated negatively with
disease severity and lacked obvious T and B cell responses.” [76]. A recent report indicates ‘ultrapotent’
antibodies identified from recovered patients’ sera that
stop CV19 attachment to host cells while disrupting the
infection machinery [58].
A systems biological assessment of immunity was presented by Arunachalam et al. [77], who noted that “The
increase in pro-inflammatory mediators in the plasma,
including IL6, TNFRNFS14, EN-RAGE, and OSM,
coupled with suppressed innate immune responses in
blood monocytes and dendritic cells (DCs) suggest a
sepsis-like clinical condition.” In this context, it has been
previously suggested that pro-inflammatory cytokines
and bacterial products in the plasma may play pathogenic roles in sepsis, and the combination of these factors could be important in determining patient survival.
Notably, the plasma of severe and ICU patients had significantly elevated levels of bacterial DNA, as measured
by PCR quantitation of the bacterial 16S ribosomal RNA
gene product. This finding was “correlated with bacterial
DNA and the plasma levels of inflammatory mediators”
[77]. The well-known infection and inflammation theory
with danger-associated molecular patterns (DAMPs) and
pathogen-associated molecular patterns (PAMPs) is supported by these findings. This finding [77] opens pathways for additional therapeutic methods and is a
welcome step toward unravelling the complex inflammatory molecular actions in CV19.
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CV19 patients with cytokine storms have fewer memory B cells, which are needed to develop a durable immune response. There appears to be a TNF alphamediated feedback loop that seems to shut down the
germinal centers that produce memory B cells for the
long-term anti-CV19 response [78]. Some immune responses are present but not as robust as those with B
cells from germinal centers. The immune response to
CV19 may be similar but not identical to the influenza
immune response.
The IFN-G action and role bear repeating as IFN-G is
related to the effect of catecholamines, specifically adrenergics. In a highly charged anxiety situation, a CV19
critically ill patient on a ventilator who has adrenergic
stimulation (i.e., adrenalin, epinephrine) blocks the action of IFN-G by inducing a shift to a Th2 cellular response that is not beneficial at this point. The use of a
beta blocker (B1 and B2 receptors, not B1 only) could
restore the function of IFN-G, as was elegantly described
by Prass et al. in brain injuries with ischemic stroke [79].

The ‘droplet’ supremacy
A ‘droplet’ is a ‘droplet’, or is it something else?
It is generally accepted that CV19 travels from person
to person on a droplet and that both are carried by the
force of a sneeze or cough or some waft through air or
as an aerosol. Webster defines ‘droplet’ as “a tiny drop,
or a blob, driblet, drip, drop or a glob.” A ‘drop’ is further defined as “the quantity of fluid that falls in one
spherical mass” and ‘a dose of medicine measured by
drops or the smallest practical unit of liquid measure”.
Wallensky further adds that the milieu includes an aerosol as a part of the ‘droplet cloud’, which is anything less
than five microns in size, with droplets ranging from five
to ten microns in size [80]. These definitions lead to a
dilemma of defining what it is that CV19 actually travels
on! Has anyone ever seen or proven that a CV19 is on
within a ‘droplet’? Is there truly a structure that can be
identified as the vehicle CV19 travels on/with or in? Can
we modify the ‘droplet’ or a structure that CV19 travels
on, with or amid so that CV 19 cannot escape, if it is indeed in, on or amid ‘droplets’? Is it truly carried ‘by’ or
‘with’ droplets or simply by the air flow from a cough,
sneeze, breath or ‘by the wind’ as an aerosol or in ‘droplets? ‘Amid’ droplets may be an appropriate description
since CV19 is likely amid a blob or a glob of moisture
and other ‘stuff’ in the breath/wind or sputum of the
CV19 carrier.
A recent paper addressed the issue of detection and
quantification of CV19 by ‘droplet’ digital PCR from
nasal swabs but failed to differentiate the actual ‘droplet’
status of CV19. However, additional useful data derived
from the study could be used as a better and improved
CV19 positive or negative test [81]. The pH of the
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‘droplet’ cloud was not studied, and it may be useful to
do so. At the ‘droplet’ stage of its accidental journey and
search for an acceptable environment and receptor site,
CV19 likely does not mutate. If the pH can be brought
to an unsurvivable value for CV19 in the ‘droplet’ or air
cloud or aerosol stage (i.e., to basic pH), then that may
plausibly become a critically important timing and opportunistic strategy to stop host receptor site entry. All
fluids and viral component proteins or amino acids
within the ‘air’ also have an optimal and functional pH.
Can the ‘air’ carrying CV19 be made slightly alkaline to
decrease CV19 viability? Perhaps the masks worn by all
can be impregnated by a basic environment-inducing
agent to help incapacitate CV19 on contact? Studies of
how long a CV19 particle ‘floats’ around in the ‘air’ are
difficult to find.

Environmental microenvironment management
CV19’s ability to enter the host cell is a purely accidental
event. The stoichiometric matching structures and the
acidic pH of receptor proteins are not accidental, but
CV19 has a better hand to play than the potential host!
How or if they affect each other stoichiometrically while
attaching and passing through will dictate whether the
proteins involved will hold ‘em or fold ‘em.
It has been reported that environmental UV-C light is
effective for killing other viruses and kills CV19 on N95
masks [82]. If UV-C light kills CV19 on mask surfaces,
why not on other surfaces? Far UV-C lights are already
in use in hospitals to sterilize surgical supplies and instruments. The UV frequencies used (~ 200-225 nm) are
safe and cause no damage. These UV lights could be
easily installed in restaurants, buses, schools, cafeterias,
theaters, and outdoors, as portable heaters are now in
outdoor diners; the uses and potential small sterile areas
are endless. The efficacy of UV-C lights depends on a
simple distance vs effect relationship, and may not be a
practical solution for CV19 eradication. It seeks expeditious study, experimentation and. This simple tool may
offer a safe, useful and inexpensive expeditious solution
to manage a part of the CV19 pandemic problem when
coupled with surface covering, washing and potential eye
protection.
Potential effects of radiation/ultrasound or other signal
energy sources could be theoretically useful if the globular CV19 structures are all the same and if the spikes are
all symmetrically positioned on each virus with predictable signal-dampening effects or potential resonance effects. There are studies of the CV19 viral coat structure,
but none have evaluated simple spike location, separation or symmetricality. This information may be useful
for eventual studies of outer CV19 coat destruction, disrupting its structural strength, integrity, and stability,
and potential theoretical response to ultrasound or other
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energy-based resonance matched signal sources. UV
light at resonant frequencies of ~ 222 nm seems to be efficacious in killing CV19 [82] on small areas and surfaces. Why is this particular frequency effective? Are
there other frequencies that may be helpful to apply as
above in order to kill CV19? How does this UV light
and frequency kill CV19? Hand held UV-lights are used
to clean surfaces and kill viruses and surgical supplies.
The proteins (‘S’, TMPRSS2, and furin) and their constituent amino acids or appendages in the CV19 spike
and ACE2/ARB receptor are also prime study targets to
determine their properties and potential for nonnative
denaturation, environmental manipulation and pH
changes.
The mouth/oral cavity and pharynx along with nasal
passages or conjunctivae are the main entry portals for
droplets and aerosols and can likely tolerate a larger
change in pH to make the environment unfavorable for
CV19. The nasal passages and oral cavity appear important as environmental modification targets because of the
ACE2/ARB receptor sites found there. Is CV19 in the
mouth/oropharynx still in, on or with its droplet on the
way to the trachea and lungs? Are nasal passage studies
are underway to investigate prevention of CV19 entry
into nasal goblet cells using nasal sprays, nanobodies
and old repurposed disinfecting solution applications
[83]? Does CV19 travel to other organs via blood vessel
distribution or by catching a ride on a protein ‘taxi’, such
as heparin? For example, HIV hitches a ride on platelets
[26]. There may be many viral properties similar to those
of HIV or other viruses. External pH of CV19 environment as found in the host before or during acceptor site
attachment and transit may be changed to an unacceptable pH for CV19 survival, within host tolerability.

pH
The vascular receptor environment and most other pHdependent sites for physiological and drug effects cannot
tolerate a large swing in pH, with the exception of the
duodenum, with a large pH swing of ~ 5.6–8.0. The normal blood/serum and overall tissue/body pH is ~ 7.35–
7.45, which is tightly controlled by respiratory, renal and
chemical/phosphate buffering systems. Further studies
may demonstrate a more general method of modifying
the conformational milieu surrounding the receptor site
by changing the local environmental pH within safe host
physiologic parameters to induce denaturation. pH is defined as “a value to express acidity and alkalinity” based
on the concentration of H+ ions by means of a logarithmic function defined by S.P.L Sorensen in 1909 as he
wrote in his book “Ueber die Messung und die Bedeutung der Wasserstoff ionen konzentration bei enzymatischen Prozessen.” This may be translated into English
as “On the measurement and the meaning of the acid
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ion concentration in enzymatic processes.”[Springer Verlag, 1909] It is important to understand that when the
pH of a solution is decreased by one unit from neutral
7.0 to 6.9, the H+ concentration has increased tenfold.
Small pH changes have tremendous consequences on
protein structures and functions. Many current CV19
studies overlook environmental or pH effects on stoichiometric actions involving ligand or receptor site proteins or their intracellular, intranuclear and endosomal
environments. While it is true that viruses do not have a
pH per se, their glycoproteins and carbohydrate appendages do have optimal and minimal pH functional ranges.
pH is of primary importance to proteins, receptors, and
intracellular or nuclear micro-environmental functions.
Thus pH manipulation may be a feasible method to
affect protein structure changes, folding, denaturing and
function. Serine, for example, as a part of the CV19
spike glycoprotein responsible for attachment to the
ACE2/ARB receptor after being ‘activated’ by TMPRSS2
from the ACE2/ARB receptor, is acidic and could be
amenable to a small environmental or pH manipulation
toward the basic range and potentially inactivated as
noted above in the heparan SO4 discussion. Both the ‘S’
protein, TMPRSS2 and furin have serine as a part of
their structures. pH environmental changes cause protein ionization, which may induce morphological
changes and an inability to function.
The body has many sites of varying pH that can accommodate receptor actions from many different drugs,
chemical moieties, proteins, enzymes or microbes, including viruses. Denaturing by inhospitable pH causes
protein biological and chemical activity to be lost or
changed. All structural degrees beyond the primary
structure are changed when a protein or nucleic acid is
denatured. It is well known that extreme pH changes
affect some peptide bonds, while serine and threonine
are destroyed by an alkaline/basic environment. This
phenomenon may provide an opportunity for study of a
potentially important useful therapy. It is posited that
environmental factors in the ACE2/ARB and ligand receptor surroundings affect protein structure and folding
and that pH may be a likely factor. Protein folding or
unfolding can be initiated by altering the pH. Will CV19
hold ‘em or fold ‘em in the event of a pH change sufficient to make a change in the structure and function, as
described by Zhang [83]? It is highly plausible that a
change to basic pH or less acidic pH may inhibit furin
activity. Endosomal and Golgi acidity may also potentially be blocked with niclosamide, which is available on
the US market as a repurposed drug.
As a rule, nothing is transported across a membrane
in its ionized state. Changes in pH affect the amino acids
and ionizable groups and residues of proteins. Once ionized by pH changes, folding of the protein can occur,
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dictating structural and functional changes [84].
Ionization and electrical properties are important in all
stoichiometric receptor functions. In the case of CV19,
the priming action of the ‘S’ protein changes it to an acceptable form by induced folding in a supportive pH
acidic environment. It does not adopt its needed ‘induced fit’ until cleavage by furin. While we know that
within the receptor site, the pH is acidic, we do not
know any other features within the receptor site. For example, does the receptor channel have Na + or Ca++
gates that depend on other factors? What would be the
effect of a pH change in and inside the receptor site region? The receptor site and the proteins of this active
and mutating virus are likely sensitive to pH changes
and manipulation, inducing denaturation. Denaturing
[folding] a protein may include losing a hydrogen bond,
a disulfide bond, a connector salt bridge, or a nonpolar
covalent bond and cause loss of function. The need to
tolerate small pH fluctuations to carry out their functions is generally characteristic of most cells. Talley and
Alexov [85] address the issue of whether a protein or
‘action’ molecule can tolerate small alterations in pH
and structure for function. They conclude by saying that
“biological macromolecules have a necessity to tolerate
small pH fluctuations”, “that such a scenario could be
achieved if the pH-optimum of activity is similar to the
characteristic pH of the subcellular compartment because the activity does not change much around the pH
optimum”, and “at the same time, keeping activity unchanged upon pH fluctuations will require the 3D structure of the corresponding protein to maintain its
structural integrity”.
The notion of variable and differential pH in different
cellular components noted in this paper and its application to CV19 players is supported by Elferich et al. [86]
as they explain pro-peptide ‘convertases’ and how they
regulate activation of ‘their protease domains by sensing
the organellar pH within the secretory pathway”. They
support one of the basic notions posed in this paper by
highlighting the relationship of furin and its relationship
to organellar pH. Elferich et al. [86] related evolutionary
analysis to the proportion of histidine residues within
pro-peptide proteases, specifically furin. They state that
furin “activates in the TGN (Tri-golgi network) at a pH
of 6.5 (acidic).“ They reason that the acid-base balancing
is slower than the histidine hydrogen exchange at basic
pH values, noting the importance of the chemical reaction speed of different entities. They concluded by stating that “they demonstrated the pKa of the conserved
histidine in pro-protein ‘convertase’ is acid shifted with
furin and consistent with its lower pH of activation”
[86]. An earlier paper by Feliciangeli et al. [87] identified
a pH sensor in the furin pro-peptide that regulates enzyme activation and showed that furin activation occurs
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in the endoplasmic reticulum, and that furin has a conserved histidine that acts as a pH sensor. In support,
Williamson et al. [30] further concluded that “Different
spatial distributions of histidine residues modulate the
activation pH of pro-protein convertases”, such as furin.
Noted is also that furin may seek a specific amino acid
sequence for cleavage supporting Coutard’s et al. report
[33]. Talley and Alexov [85] state that “….only activity is
biologically important, that macromolecules can tolerate
small pH fluctuations that are inevitable with cellular
function“, and that “our findings rationalize the efforts
of correlating the pH of maximum stability and the
characteristic pH of subcellular compartments since only
the pH of activity is subject to evolutionary pressure”.
More specifically, one of the central assertions of this
paper is that the pH of the extracellular environment, receptor site and intracellular compartments appears critically important in enabling CV19.
Williamson et al. [88] reveal the pH-dependent activation of furin via a complicated combination of structural,
mathematical and molecular dynamic simulations that
suggest that “His-69 from the furin pro-domain serving
as the pH sensor close to the TGN triggers movement
of a loop region in the pro-peptide that modulates access
to the cleavage site and thus allows for the tight pH
regulation of furin activation”. Williamson et al’s [88]
work establishes a model for further study, and potential
furin control via environmental and pH manipulation, as
espoused in this paper.
Acidic transmembrane glycoproteins have attached
carbohydrate appendages whose response to minimal
pH environmental changes may induce structural folding
changes. One source states that the optimal pH for renal
ACE2/ARB receptor activity is ~ 5.5–7.5 [89]. Does
CV19 adapt to the various tissue environments via a
small but still ACE2/ARB-compatible stoichiometric fit
adjustment? The normal pH range in the oral cavity is
large, ~ 6.8–7.5, from acidic to alkaline. The nasal cavity
mucosa is 5.5–6.5 and increases to 7.2–8.3 with rhinitis.
The fact that rhinitis caused by CV19 may also increase
nasal pH has not been addressed and may also be a potential pH change CV19 therapeutic target since furin
prefers an acidic environment for activity. Hull addressed the issue of changing nasal pH with nasal medicine application in patients afflicted with the common
cold [90], with some success. It is plausible that CV19
may be destroyed or blocked by nasal receptor environmental pH adjustment [91]. England et al. found nasal
pH to be a reliable parameter [92].
The notion of pH manipulation as a plausible therapy
has been introduced for both acidic pre-entry, acidic
intracellular Golgi body and endosomal pH manipulation [61]. It is apparent that furin favors an acidic environment for cleavage activity [86]. Manipulating the pH
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of select organelles and external environment appears a
plausible method to stop furin which seeks acidic environments for activity. Potentially early heparanSO4 action could be interfered with a basic environment. An
earlier report of pH dependent SARS coronavirus entry
was mediated by the spike glycoprotein may have been a
predictor of current entry events [93].

Connecting thoughts: hold ‘em or fold ‘em?
The above discussions explore spike protein characteristics and chemistry, receptor site protein action, heparan
SO4 & heparin involvement, pH effects on pertinent
proteins, furin characteristics and activities, mutation effects, immune system action, select drug repurposing,
energy needs and the role of PDE[phosphodiesterase],
translational interpretations open to modification by
newer data, an apparent Th1-to-Th2 cellular immune
shift, potential use of far UV-C light, ‘droplet’ transmission, and niclosamide action on the TCA cycle and pH
manipulation. The focus on environmental therapy and
CV19 treatment is highlighted with some specific therapeutic recommendations.
Extra and intracellular environmental management
may be possible even if and when the approaching agonist has the capability to mutate during current activity
[as CV19 does] since each protein, including the mutated protein, has its optimal pH range, including and
regardless of the current momentary structure. The
optimum environmental factor modulating extracellular
pH needed for protein function to proceed must be determined, sought and adjusted within the parameters of
host and medication tolerance. Both extra or intracellular pH and host nuclear pH changes and their effect on
furin await to be studied expeditiously at each step of
CV19’s life cycle, from ‘droplets’ and air relationships to
host entry, viral replication, exosome acquisition and
exit from the host. Furin is a common denominator in
many of these events. It must be learned: 1.How or if
furin can be blocked or its functions modified by manipulating the pH, from its creation in the endoplasmic
reticulum [87] or as it acts in organelles; 2. How to blunt
furin pH sensing; 3. How to use furin blockers [94]; 4.
How to use pH manipulation to stop CV19 and restore
health.
Extracellular receptor proteins may be more easily influenced by environmental or pH adjustment since they
are presumably more stable or easily affected proteins.
An agonist/ligand may change/mutate and still ‘fit’ a
nonmutated receptor.
The current batch of highly visible vaccines being developed has efficacy according to reports. Since CV19
has the potential to mutate on demand, will they still be
effective, or is a new vaccine needed for each mutant?
Environmental or pH adjustments for CV19 and ACE2/
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ARB protein changes have the potential to become a
more universally effective therapeutic tool regardless of
the current mutational structure or differing microbial
or chemical agonists/ligands. As said the main steps in
the infection pathway are random attachment, entry, fusion, replication, and endocytic and exocytic membrane
site activity, with each step having its own requirements.
There is still much to be learned about these steps, although enough may be known to begin clinical studies.
This translational thought experiment is offered as a
possible explanation and exploratory therapeutic
beginning.
This translational thought experiment presents a potential coalescence of molecular environmental manipulation of pH in the context of ‘hold ‘em or fold ‘em’ and
furin role interactions. Wu-Dunn and Spear support the
environmental effect notions and focus in this paper [61]
in an elegant and wide-ranging paper. Jurgeit et al. proposed the use of niclosamide beyond its current limited
application [60]. As mentioned above, Niclosamide has
been safely used for over 40 years in humans as an anthelmintic and has desirable and potentially efficacious
actions in human illnesses and intracellular or intranuclear effects. Niclosamide uncouples oxidative phosphorylation and hence potentially denies a critical energy
source for cellular, microbiological or viral and CV19 action [60, 61]. Niclosamide also blocks endosomal acidification. Could it also block receptor site acidification to
potentially halt CV19 entry? These are known basic requirements for furin action, its production and activity
[87]. Niclosamide is available as a drug in the US market
and has widespread effects on viral infections that could
be useful as one of several drugs in a cocktail (remdesivir, niclosamide, camostat mesylate, tocilizumab, other
furin inhibitors or PDE manipulators, etc.) or potentially
alone.
The discussed repurposed drugs meet the needs to
stop CV19: halt host receptor site entry, interfere with
the energy needs of CV19 to make proteins and exit
(and the well-known increase in PDE inhibitory action
on cAMP), as well as change the pH environment to further prevent furin sensing via histidine. The repurposed
drug cocktail or combinations suggested in this paper
and the cocktails suggested by Hansen [43] and Hansen
and Baum [44] may allow the potential resuscitation of
single-target vaccine failures due to CV19 potential in
situ changes or adaptations and mutations. The predictions of multiple new mutations requiring new ‘vaccine’
development and multi-valent vaccine development
herein are emerging now and seek expeditious attention
lest we lose the progress made up to the present. The
way forward, as are additions to ‘vaccines,’ is with multivalent vaccines combined with medicine or drug cocktails on CV19 as done with influenza and HIV therapies.
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This translational thought experiment presents notions
that speak to attachment action by proteins, functions of
proteins (adhesion, attachment, receptor site function,
fusion of cell membranes), protein production in acidic
environments, cleavage by furin, sensing by furin, furin’s
need for an acidic environment for action, insertion of
specific and CV19-unique amino acid series for furin
sensing in CV19, the role of histidine as a pH sensor,
variability of histidine chemical reaction speed, proposed
models of the roles of heparan-SO4, its removal and pH
change for receptor site entry denial, mutations, and
repurposed medications already available and shown to
be safe. Various combination cocktails may be necessary
for potential treatment of resistant mutations. Two
major notions, furin control or destruction and the role
pH management were advanced. Much of the uncertainty, the unknown nature and fear of CV19 could be
ameliorated if we can control whether CV19 holds ‘em
or folds ‘em. pH control may offer some predictability of
CV19 action and behavior. It must be pointed out that a
nationwide or global-wide vaccination campaign, with
many requiring the scheduling of two separate vaccinations are labor and time intensive, and place a heavy
burden upon most states, countries, patients, support
labor forces as well as equipment needs and costs when
compared to using re-purposed medications or medication cocktails. These may plausibly work as well upon
study and trial, and are less labor intensive and costly.
The nations unable to obtain or manufacture vaccines
may be able to gain faster protection for their populations by using alternatives to vaccination upon validation
of the alternative therapies and environmental notions
offered here. While waiting for ‘vaccine’ availability issues to be solved the alternative potential solutions offered here may be a productive pathway while seeking
and awaiting vaccines. The emerging mutations add urgency to seek alternatives to vaccines.
The current and future pandemics deserve all potential
discovery and therapeutic ideas to be taken seriously and
thoroughly evaluated, regardless of how ‘Swiftian’ they
are or whether they have ever been considered before in
this newer demanding context or not. Energy-dependent
cellular activities potentially affecting host TCA/Krebs
cycle functions will likely recover rapidly once CV19 is
destroyed as they likely have for over 40 years with the
use of niclosamide. To the above suggested cocktails,
one can add a ‘newer and younger’ immune system from
autologous white blood cell infusion by either prior storage or bone-marrow sources for potential expedited return to good health [70, 71]. Both reports reflect the
essence and basis of translational thought experiments
[70, 71].
The translational thought experiments posed and suggested herein may stimulate further ideation and study.
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Timely support for the hand that CV19 plays [Hold’em
or Fold’em?] arrived from Goethe University in Frankfurt, where it was noted that ‘they have observed the
RNA folding structures of the SARS-CoV-2 genome
with which the virus controls the infection process” [95].
Enabling loop completion supporting reports include
autophagy studies that point to endolysomal deacidification which may impede furin, [96], the association of autophagy with uncontrolled inflammation and delayed or
absence of types I and III Interferons and increased cytokine production defects [97], and the plausible inhibition
endosomal uncoating ‘thus preventing endosomal actions in entry and exit by CV19 (author’s comment)’.
Autophagy control is thought to be via changes in activation phases of autophagy related genes [98]. These
comments are merely superficial indicators of an extremely complex genetic interplay that is beginning to
be unraveled.
Niclosamide is also confirmed by Gassen et al. [98] as
a potential antiviral agent as suggested in this paper before it began its prolonged editorial and review journey.
The role of cystidine peptidase control is thought to impede cell entry and replication [99]. Pislar et al. [99] note
that cathepsin inhibitors ‘dual’ inhibitory action on viral
and host by lessening the positive immune response may
support the needed multi-pronged therapeutic approach
as suggested earlier in this paper by Baum et al. [43] and
Hansen et al. [44] who also suggest a multi-pronged
therapeutic approach to counter mutation escape by
viral variants,
In addressing the activity at and of the furin cleavage
site, Xing et al. [100] note that many mutations are active at that site, and may lessen the importance of the
cleavage site. Their interesting studies seek more supporting data to unravel a complex finding. Xia et al.
[101] discuss the role of trypsin in the furin cleavage site
and its mutation or change from a ‘RRAR’ configuration
into a ‘SSAR’ configuration which appears equally effective in cleavage and viral entry, adding more confusion to
a most complex and vexing situation.
Pardhan et al. [102] review and support that the most
significant ocular symptoms by patients with CV19 infection are ‘sore eyes’. However, one source reports that there
was loss of vision by a patient infected by CV19 [103].

Conclusion
Translational thought experiments add value to science
since without them science would not progress. Translational experimental ideation, based on and referenced
with sound and proven science, deserves acknowledgment and recognition as a necessary equal partner in scientific or medical discovery and progress. To do so will
encourage huge scientific progress and pave the way to
the future.
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Will the question between Darwin’s natural selection,
where only those organisms best adapted to their environment survive, and Lamarck’s notion of adaptive force,
where organisms can alter themselves to meet the needs
of their environments be answered? The roles of furin
and pH appear to be in the midst of the chaotic environment that allows CV19 to merge Darwin’s science with
Lamarck’s contributions. Regardless of the pH of the
moment, whether external, receptor site, internal cell
site or organelle, pH becomes a major determinant of
protein or chemical structure [folding] and function. If
histidine sensing disappears or amino acid sequences
change by mutation or evolution, CV19 and its minion
furin can still be managed within host tolerance of pH
management. Furin works best in an acidic environment.
The newest emerging ‘mutant’ has an optimal pH for
function, and population penetrance may be determined
by pH influence on the players and their momentary
managed environmental pH. CV19 will change and mutate, but the role and importance of pH remains unchanged. pH management allows CV19 to hold’em or to
fold’em and plausibly grants loop completion of this
translational thought experiment and potential global
application of non-vaccine therapy. Both Darwin and
Lamarck are correct and imply separate but equal historical scientific truths.
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